Could AATD be hiding among your patients with COPD, uncontrolled asthma, or bronchiectasis?
| Estimated time to read:
The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.
Uncover how AATD can hide within your practice
Globally, 235,000 people live with alpha-1 antitrypsin deficiency (AATD) and represent 1% to 3% of the chronic obstructive pulmonary disorder (COPD) population. However, more than 90% of individuals with AATD remain undiagnosed.
Join us for an interactive fireside-style symposium
Hear from patient Karen Erickson, who will share her experience with AATD, and Rajat Walia, MD, FCCP, an expert pulmonologist, as they discuss the realities of an AATD diagnostic journey and its implications for clinical practice.
Dinner will be served during the symposium.
Through firsthand experiences and insights, attendees will explore:
- Clinical clues that may prompt consideration of AATD testing
- Practical approaches to supporting earlier diagnosis
- The personal, family, and clinical consequences of delayed identification
This unique discussion will connect the patient experience with practical clinical decision-making to help support earlier recognition of AATD in respiratory care.
REGISTER TODAY to reserve your seat. Space is limited.
Look beyond your COPD diagnosis at Booth #891
Could your COPD, emphysema, asthma, or bronchiectasis patient have AATD? Through immersive patient stories and interactive experiences, discover why AATD testing may be a critical next step for your pulmonary patients.
